TL;Dr.: In a study published in Nature Medicine, Spergel and colleagues reported interim findings from a phase 1/2 trial evaluating the safety and reactogenicity of mRNA-1083, a multicomponent vaccine targeting both seasonal influenza and SARS-CoV-2. The vaccine showed a favorable safety profile through day 28 in healthy adults aged 18 to 79, who experienced mostly Grade 1 or 2 adverse events. The immune responses against influenza and SARS-CoV-2 induced by mRNA-1083 were similar to or higher than those elicited by the licensed quadrivalent flu vaccine and the bivalent mRNA COVID-19 vaccine. These findings support continued evaluation of mRNA-1083 as a single-dose option for dual respiratory protection.